TLDR Pfizer filed two lawsuits against Novo Nordisk over competing $9 billion Metsera bid Novo’s 30-month closing period compared to Pfizer’s nine-month timeline sparks antitrust concerns Metsera board favors Novo’s offer after shareholder-driven board overhaul Delaware judge hears case Tuesday as Pfizer faces deadline to submit higher bid Pfizer sees Metsera as key entry into [...] The post Pfizer (PFE) Stock: Company Files Dual Lawsuits Against Novo Nordisk Over Metsera Deal appeared first on Blockonomi.TLDR Pfizer filed two lawsuits against Novo Nordisk over competing $9 billion Metsera bid Novo’s 30-month closing period compared to Pfizer’s nine-month timeline sparks antitrust concerns Metsera board favors Novo’s offer after shareholder-driven board overhaul Delaware judge hears case Tuesday as Pfizer faces deadline to submit higher bid Pfizer sees Metsera as key entry into [...] The post Pfizer (PFE) Stock: Company Files Dual Lawsuits Against Novo Nordisk Over Metsera Deal appeared first on Blockonomi.

Pfizer (PFE) Stock: Company Files Dual Lawsuits Against Novo Nordisk Over Metsera Deal

2025/11/04 19:58

TLDR

  • Pfizer filed two lawsuits against Novo Nordisk over competing $9 billion Metsera bid
  • Novo’s 30-month closing period compared to Pfizer’s nine-month timeline sparks antitrust concerns
  • Metsera board favors Novo’s offer after shareholder-driven board overhaul
  • Delaware judge hears case Tuesday as Pfizer faces deadline to submit higher bid
  • Pfizer sees Metsera as key entry into $150 billion obesity drug market

Pfizer escalated its battle for Metsera on Monday with two separate lawsuits against Novo Nordisk. The legal action challenges the Danish company’s $9 billion competing bid for the obesity drug developer.

Pfizer agreed to acquire Metsera for up to $7.3 billion in September. The deal came after months of private negotiations between Pfizer and Novo.

Metsera had rejected Novo’s offers six times before citing antitrust concerns. But last week, Novo’s top investor restructured Metsera’s board.


PFE Stock Card
Pfizer Inc., PFE

The Danish drugmaker then launched a fresh $9 billion unsolicited bid. Metsera’s new board declared the offer superior and gave Pfizer until Tuesday to counter.

Pfizer Questions Timeline and Motives

Pfizer’s main complaint targets Novo’s proposed 30-month closing period. The lawsuit argues this timeline would delay Metsera’s obesity treatments from reaching patients.

Pfizer’s original deal included a nine-month closing window. The company received early antitrust clearance on October 31.

The federal complaint claims Novo isn’t making a genuine acquisition attempt. Instead, Pfizer characterizes the bid as a strategy to block competition.

Court documents show Novo Nordisk offered $6.5 billion upfront before regulatory review. Pfizer says the deal includes restrictive terms that would slow clinical development.

Metsera is developing monthly injectable obesity drugs. Current market leaders Wegovy and Zepbound require weekly injections.

Analysts forecast the obesity drug market could reach $150 billion annually. Metsera’s experimental therapies could generate $5 billion in sales.

Both Sides Push Back Hard

Metsera accused Pfizer of manipulating the legal timeline. The biotech noted Pfizer knew about Novo’s bid on October 25 but delayed filing suit.

Novo Nordisk defended its position strongly. The company said it followed all restrictions in Pfizer’s merger agreement.

Novo said it would use its expertise to accelerate Metsera’s commercialization. The company positioned itself as the better partner for patients.

Market Reaction and Next Steps

Vice Chancellor Morgan Zurn scheduled a hearing for Tuesday morning. The session could determine which pharmaceutical giant wins control of Metsera.

Pfizer shares closed flat on Monday. Metsera stock fell 3.7% to $60.73.

Novo Nordisk shares dropped less than 1%. Pfizer’s antitrust review for its Metsera deal received early termination on October 31.

The Tuesday deadline puts pressure on Pfizer to either raise its bid or rely on the courts. Metsera’s board appears to favor Novo’s higher offer despite the litigation.

The post Pfizer (PFE) Stock: Company Files Dual Lawsuits Against Novo Nordisk Over Metsera Deal appeared first on Blockonomi.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

Crypto Market Cap Edges Up 2% as Bitcoin Approaches $118K After Fed Rate Trim

Crypto Market Cap Edges Up 2% as Bitcoin Approaches $118K After Fed Rate Trim

The global crypto market cap rose 2% to $4.2 trillion on Thursday, lifted by Bitcoin’s steady climb toward $118,000 after the Fed delivered its first interest rate cut of the year. Gains were measured, however, as investors weighed the central bank’s cautious tone on future policy moves. Bitcoin last traded 1% higher at $117,426. Ether rose 2.8% to $4,609. XRP also gained, rising 2.9% to $3.10. Fed Chair Jerome Powell described Wednesday’s quarter-point reduction as a risk-management step, stressing that policymakers were in no hurry to speed up the easing cycle. His comments dampened expectations of more aggressive cuts, limiting enthusiasm across risk assets. Traders Anticipated Fed Rate Trim, Leaving Little Room for Surprise Rally The Federal Open Market Committee voted 11-to-1 to lower the benchmark lending rate to a range of 4.00% to 4.25%. The sole dissent came from newly appointed governor Stephen Miran, who pushed for a half-point cut. Traders were largely prepared for the move. Futures markets tracked by the CME FedWatch tool had assigned a 96% probability to a 25 basis point cut, making the decision widely anticipated. That advance positioning meant much of the potential boost was already priced in, creating what analysts described as a “buy the rumour, sell the news” environment. Fed Rate Decision Creates Conditions for Crypto, But Traders Still Hold Back Andrew Forson, president of DeFi Technologies, said lower borrowing costs would eventually steer more money toward digital assets. “A lower cost of capital indicates more capital flows into the digital assets space because the risk hurdle rate for money is lower,” he noted. He added that staking products and blockchain projects could become attractive alternatives to traditional bonds, offering both yield and appreciation. Despite the cut, crypto markets remained calm. Open interest in Bitcoin futures held steady and no major liquidation cascades followed the Fed’s decision. Analysts pointed to Powell’s language and upcoming economic data as the key factors for traders before building larger positions. Powell’s Caution Tempers Immediate Impact of Fed Rate Move on Crypto Markets History also suggests crypto rallies after rate cuts often take time. When the Fed eased in Dec. 2024, Bitcoin briefly surged 5% cent before consolidating, with sustained gains arriving only weeks later. This time, market watchers are bracing for a similar pattern. Powell’s insistence on caution, combined with uncertainty around inflation and growth, has kept short-term volatility muted even as sentiment for risk assets improves. BitMine’s Tom Lee this week predicted that Bitcoin and Ether could deliver “monster gains” in the next three months if the Fed continues on an easing path. His view echoes broader expectations that liquidity-sensitive assets will outperform once the cycle gathers pace. For now, the crypto sector has digested the Fed’s move with restraint. Traders remain focused on signals from the central bank’s October meeting to determine whether Wednesday’s step marks the beginning of a broader policy shift or just a one-off adjustment
Share
CryptoNews2025/09/18 13:14